Document is current
Any future updates will be listed below
-
Authors
Laurence, Valérie
Jehanno, Nina https://orcid.org/0000-0002-4370-8223
Dureau, Sylvain
Mous, Lieke
Claude, Line
Ballet, Stelly
Pierron, Gaëlle https://orcid.org/0000-0002-2536-7680
Gaspar, Nathalie https://orcid.org/0000-0002-1827-8903
Brahmi, Mehdi
Valentin, Thibaud https://orcid.org/0000-0002-3189-8445
Revon-Rivière, Gabriel
Lervat, Cyril
Probert, Jamie
Entz-Werle, Natacha
Mansuy, Ludovic
Plantaz, Dominique
Rios, Maria
Saumet, Laure
Vérité, Cécile
Castex, Marie-Pierre
Thebaud, Estelle
Cassou-Mounat, Thibaut
Plissonnier, Anne-Sophie
Dieppedale, Jennifer
Delattre, Olivier
Legrier, Marie-Emmanuelle
Marec-Bérard, Perrine
Gouin, François
Berlanga, Pablo
Cordero, Camille
Surdez, Didier
Corradini, Nadège https://orcid.org/0000-0002-1942-1222
- License Information
-
More Information
Article History
Received: 2 June 2025
Revised: 30 September 2025
Accepted: 28 October 2025
First Online: 17 November 2025
Competing interests
: PB has consulting role (institutional funding) for Recordati and Merck, drugs for trials from Bayer, participation in educational activities organised by Recordati and is Member of the Executive Committee of the SIOPEN (European neuroblastoma research cooperative group), organisation which receives royalties for the sales of dinutuximab beta.
